·
Samsung Bioepis recorded Q1’26 revenue of
KRW 454.9 billion and operating profit of KRW 144.0 billion
CORRECTION...by Samsung Epis Holdings
(BUSINESS
WIRE) -- Third paragraph, second sentence of release should read:
Revenue and operating profit in the first quarter increased by 14% (KRW 54.3
billion) and 13% (KRW 16.1 billion) in year-over-year (YoY), respectively.
(instead of Revenue and operating profit in the fourth quarter increased by 14%
(KRW 54.3 billion) and 13% (KRW 16.1 billion) in year-over-year (YoY),
respectively.).
The updated release reads:
SAMSUNG EPIS HOLDINGS
REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS
Samsung Epis Holdings (KRX: 0126Z0), an investment company
dedicated to innovations in biopharmaceuticals and biotechnology, today
announced its financial results for the first quarter of fiscal year 2026.
“Samsung Bioepis delivered solid growth this quarter driven
by continued momentum across our biosimilar portfolio," said Kyung-Ah Kim,
President and Chief Executive Officer (CEO) of Samsung Epis Holdings. “We are
further strengthening our position through new global partnerships and
continued portfolio expansion. As we mark the 10th anniversary
of the launch of our first biosimilar in Europe, we remain focused on building
on our legacy while investing strategically to support long-term growth. We
remain committed to delivering sustainable value for our shareholders.”
First Quarter 2026 Results
On a standalone basis, in the first quarter of 2026, Samsung
Bioepis posted a revenue of KRW 454.9 billion with an operating profit of KRW
144.0 billion. Revenue and operating profit in the first quarter increased by 14%
(KRW 54.3 billion) and 13% (KRW 16.1 billion) in year-over-year (YoY),
respectively.
First quarter growth surpassed the January 2025 guidance by
more than 10%, reflecting stronger-than-expected performance across the
business.
Samsung Epis Holdings posted a consolidated
revenue of KRW 453.9 billion and operating profit of KRW 90.5 billion. Non-cash
accounting adjustments, including amortization of purchase price allocation
(PPA)-related development costs, are reflected in consolidated revenue and operating
profit, following a consolidated revenue of KRW 251.7 billion and operating
loss of KRW 63.6 billion in November and December 2025.
|
[Samsung
Bioepis Earnings, KRW billion] |
|
||||
|
|
Q1’24 |
Q1’25 |
Q1’26 |
YoY Change |
|
|
Revenue |
280.1 |
400.6 |
454.9 |
+54.3 (+14%) |
|
|
Operating Profit |
38.1 |
127.9 |
144.0 |
+16.1 (+13%) |
|
Business Updates
·
In October 2025, Samsung Bioepis entered into a private label
partnership with CVS Caremark, the Pharmacy Benefit Manager (PBM) division of
CVS Health, for OSPOMYV™ (denosumab-dssb), a biosimilar to Prolia1.
·
BENEPALI™ (etanercept), Samsung Bioepis’ first biosimilar in
Europe, continues to maintain its leadership position in the market as it
celebrates its 10th anniversary
in Europe.
·
In March, Samsung Bioepis expanded its development and
commercialization partnership with Sandoz, on up to five biosimilar candidates
including SB36, a biosimilar candidate referencing Entyvio (vedolizumab), in
multiple markets.
·
Also in March, a Phase 1 first-in-human clinical trial for
Samsung Bioepis’s first novel antibody-drug conjugate (ADC) candidate, SBE303,
has begun. Following the announcement, the company also presented a poster
presentation of its nonclinical data at the American Association for Cancer
Research (AACR) 2026 on April 20th which demonstrates its encouraging efficacy,
safety, tolerability and a promising ability to work in combination with
existing immuno-oncology therapies.
·
Samsung Bioepis’s second novel ADC candidate, SBE313, is
currently in nonclinical development in collaboration with Phrontline
Biopharma.
Disclaimer
This document contains ‘forward-looking statements’ regarding
future expectations, projections, plans, and anticipation. ‘Forward-looking
statements’ are matters that pertain to the Company’s future business and
financial performance, and are subject to uncertainties such as trends in
domestic and international financial markets, including but not limited to
fluctuations in exchange rates and/or interest rates.
‘Forward-looking statements,’ by their nature, addresses
matters that may be uncertain; actual results may be materially different from
those expressed in this document.
About Samsung Epis Holdings Co., Ltd.
As an investment holdings company dedicated to
biopharmaceuticals and biotechnology, Samsung Epis Holdings aims to maximize
corporate and shareholder value through proactive R&D and investment and
optimize business strategies for its subsidiaries, Samsung Bioepis and Epis
NexLab. Samsung Epis Holdings continues to embrace future challenges and drive
innovation by identifying new growth drivers and strengthening global
collaboration platforms, thereby laying a solid foundation for the continued
growth of its subsidiaries. For more information about Samsung Epis Holdings,
please visit: www.samsungepisholdings.com.
About Samsung Bioepis Co., Ltd.
Established in 2012, Samsung Bioepis is a biopharmaceutical
company committed to realizing healthcare that is accessible to everyone.
Through innovations in product development and a firm commitment to quality,
Samsung Bioepis aims to become the world's leading biopharmaceutical company.
Samsung Bioepis continues to advance a broad pipeline of biologic candidates
that cover a spectrum of therapeutic areas, including immunology, oncology,
ophthalmology, hematology, nephrology, neurology, and endocrinology. For more
information, please visit www.samsungbioepis.com and follow
us on LinkedIn and X.
About Epis NexLab Co., Ltd.
Established in 2025 as a 100% owned subsidiary of Samsung
Epis Holdings, Epis NexLab is committed to driving innovation through the
development of next-generation biotechnology platforms. By transforming highly
scalable peptide-related technologies into development platforms, Epis NexLab
is focused on the discovery of innovative treatment modalities for the
development of multiple therapeutic candidates targeting a wide range of
diseases. For more information about Epis NexLab, please visit: www.samsungepisholdings.com.
Reference
1 Prolia is a registered trademark of Amgen Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260422191520/en/
Permalink
https://www.aetoswire.com/en/news/2304202654496
Contacts
Media Contact
Yoon Kim, yoon1.kim@samsung.com
Anna Nayun
Kim, nayun86.kim@samsung.com
No comments:
Post a Comment